Dopamine is a catecholamine used widely in critically ill patients and those undergoing major surgery, often as a 'renal protective' agent. Direct renal vasodilatation with 'low-dose' dopamine is the widely accepted basis for its use -hence the term 'renal dose' dopamine.
assumes that hypoperfusion is a common pathophysiological factor, it mayor may not be present in any individual patient.
Dopamine is an endogenous catecholamine, often used empirically as a 'renal protective' agent in patients undergoing major surgery and the critically ill. Direct renal vasodilatation and augmentation of renal blood flow (RBF) is the widely accepted basis for the use of 'low-dose' dopamine -hence the term 'renal dose dopamine'. However, recent evidence has revealed that the renal effects of this agent are far more complex ( Figure I) . Moreover, some ofthese effects may be undesirable in the 'at-risk' kidney.
The increased renal blood flow (RBF) found with 'low-dose' dopamine, (i.e. < 5 ~g!kg!min), may be largely attributable to its inotropic (myocardial)
This paper was the winning entry for the 1991 Bird Products/Tag Medical Prize for the best State of the Art review in the field of Intensive Care, held under the auspices at the Australian and New Zealand Intensive Care Society. action. Similar increases in RBF can also be demonstrated with other (non-dopaminergic) inotropes. In addition, the diuresis commonly seen following dopamine administration is now known to be due to a direct renal tubular (or 'diuretic') action.
The earlier evidence for significant direct renal vasodilation in response to dopamine has been brought into question by more recent research. Furthermore, increasing knowledge regarding the pathophysiology of ischaemic acute renal failure suggests that dopamine may even mask important signs of renal ischaemia. Therefore we need to reconsider the question, is dopamine beneficial to renal function?
Before examining the effect of dopamine on renal function (and its use in renal dysfunction), it is prudent to review some aspects of renal pathophysiology, including the concept of altered RBF autoregulation, the concept of oxygen 'supply and demand' in relation to tubular function, and how this impinges on ischaemic acute renal failure.
Renal blood flow and oxygen delivery
Total RBF is approximately 1.2 llmin, or 20% of cardiac output l4 and therefore total renal oxygen delivery is very high -240 ml 02/minute. RBF has a wide range of physiological variation (12-30%) 14 and is influenced by many factors l4 . 16 such as sodium intake, protein intake, metabolic rate, emotional status, the level of endogenous catecholamines, posture, etc. Furthermore the renal vasculature is normally maximally vasodilated, and has little (10 to 20%) vasodilator reserve. 17 Renal oxygen consumption is also high (18 to 20 ml 02/min),17 particularly in the cortex, and primarily determined by sodium reabsorbtion. Nevertheless, total renal oxygen delivery is well in excess of this metabolic requirement with the kidney extracting only 8-10% of available oxygen -well below most other organs -and this results in a high renal vein P02 (70 mmHg).
If global oxygen delivery is far greater than renal metabolic demand, why then should we face this paradox: 'Ischaemic damage readily occurs in (such a well) oxygenated organ'?19 Why is it that in animal models of ischaemic ARF, 'Hypoxic injury occurs well in advance of a severe reduction in total oxygen delivery'?20
Such a high global oxygen delivery could imply two possibilities:
(i) that RBF is autoregulated by a mechanism other than metabolic rate; or (ii) that unlike other organs, the kidney requires a high oxygen delivery to prevent tissue hypoxia. There is evidence to suggest both hypotheses are true.
Autoregulation of renal blood flow in health and disease
In the kidney, blood flow is in fact autoregulated primarily to maintain glomerular filtration rate (GFR)16 and body sodium balance, rather than to meet renal metabolic demand. Both RBF and GFR are well maintained, and remain fairly constant over a wide range of systemic blood pressure ( Figure 2 ), unless perfusion pressure falls below their autoregulatory thresholds. 14 Mean Arterial Pressure FIGURE 2.-EfTect of perfusion pressure on RBF, GFR, and urine output. This is not always the case in pathological states. A better knowledge of the pathophysiology of RBF could help us to more appropriately direct renal therapy. Unfortunately only limited animal data on the RBF changes in haemorrhagic, cardiogenic, obstructure and septic shock, are available, and generally only from anaesthetised animals.
Haemorrhagic shock is usually thought to be associated with a fall in RBF31. However, most of the studies have been carried out on animals under general anaesthesia, which of itself has adverse effects on RBF. General anaesthesia results in activation of the sympathetic nervous system,22,23 an increase in renin and angiotensin 11 levels, a reduction in urine output,24-28 and impairment of autoregulation_ 18 ,27 Mechanical ventilation 29 and surgical stress 30 also have adverse renal effects_ Vatner 31 found that following severe haemorrhage (26 ml/kg) in anaesthetised dogs, RBF was markedly reduced and renal vascular resistance elevated_ However, in conscious dogs subjected to the same blood loss, RBF was well maintained, and renal vascular resistance actually fell, despite a high level of sympathetic tone and systemic vascular resistance_ . Even in cardiogenic and obstructive shock, there is some evidence that RBF is well maintained. 32.33 In a recent study32 using conscious dogs, cardiac output was reduced by the injection of autologous blood clot into the pulmonary circulation, to simulate acute pulmonary embolism. Even after cardiac output had fallen to 55% of baseline and systemic vascular resistance had risen by 80% (keeping MAP unchanged), RBF fell by only 15% and creatinine clearance remained unaltered.
Hyperdynamic circulation produced by pregnancy34 is associated with an increase in RBF, whereas in thyrotoxicosis 14 there is a relative fall. In hyperdynamic sepsis, RBF may rise or fall depending on the combined effect of perfusion pressure and renal vascular resistance. 35 For example, in hypotensive sepsis RBF is reduced. 35 -37 In hyperdynamic normotensive sepsis both animaP8-40 and human 6 data reveal a rise in RBF associated with a rise in cardiac output.
Sepsis is associated with an imbalance in the excretion of vasoactive prostaglandin metabolites. 36 ,41-45 During sepsis a fall in RBF is associated with increased thromboxane A2 excretion,43 whereas improvement in RBF is associated with increased PGE 2 production. 44 Thus in the septic state there may be a disorder of renal autoregulation, resulting in a pressure-dependent RBF.
Heterogeneous renal oxygen distribution
Although renal oxygen delivery is much higher than its oxygen consumption, the internal distribution of that oxygen is not uniform. Even under healthy states, the peritubular P0 2 has been shown to be lower than renal vein P0 2 and independent of arterial P0 2 .19.20.46 Why does this situation exist? The anatomy of the renal microcirculation 19 has two interesting features which appear to set limits on the tubular cell oxygen supply -namely a 'portal' circulation, and a vascular 'countercurrent' mechanism.
The 'portal' circulation describes the presence of two separate but connected capillary networks. Blood first passes through the glomerular capillary network, then on through the efferent arteriole to a second capillary network surrounding the tubular structures. Unlike capillary beds in other organs, renal metabolic rate has little autoregulatory influence over the peritubular-capillary blood flow.
The capillary network (vasa recta) follows the loop of Henle down into the outer cortex and medulla, and the capillary P0 2 is subjected to a 'countercurrent' diluting effect. In a similar way to the 'countercurrent' rise in sodium concentration of the tubular fluid, the capillary P0 2 is reduced 19 (Figure 3 ). This results in a critical drop in peritubular-capillary P0 2 down to 8 to 10 mmHg_ Even a small drop in total RBF could potentially reduce this P0 2 to below the hypoxic threshold. Cortical capillaries also have a P0 2 which is lower than renal vein Po 2 , but this is less well explained by this countercurrent mechanism. 20 ,46
Tubular cell hypoxia and oxygen supply/demand balance
The primary function of renal tubular cells is reabsorption of sodium and water. Each day 27,000 mmol of sodium is filtered and 99.9% is reabsorbed. 1 4-16 Reabsorbtion is a highly energydependent process and accounts for most of the oxygen utilisation by the kidney_ An increase in glomerular filtration will increase sodium load to the tubule and result in an increase in both sodium reabsorbtion and renal oxygen consumption. A fall in GFR will have the opposite effect. Thus the kidney may be considered to show physiological 'oxygen supply-dependency'. Moreover, the region of the kidney with the highest metabolic demand is the very region which is most subject to hypoxia. Reabsorbtion of sodium may thus predispose to tubular cell hypoxia in situations where the regional oxygen supply is reduced. 19, 20, 47 The stage is thus set for tubular cell hypoxia and tubular dysfunction should either oxygen delivery (e.g. RBF) fall, or tubular cell oxygen demand (i.e. sodium reabsorbtion) rise ( Figure 4 ). Even a small drop in RBF could theoretically jeopardise tubular function and predispose to acute renal failure. Recent investigations suggest that the tubules are indeed susceptible to hypoxic damage even following a small fall in renal oxygen delivery. 20 Does the kidney have any protective mechanism to prevent tubular hypoxia? Yes, fortunately it does, in the form of the tubulo-glomerular feedback (TGF) mechanism. Tubulo-glomerular feedback ~ubulo-glomerular feedback 14 -16 ,47 ( Figure 5 ) is an Important local autoregulatory function of each nephron. The stimulus appears to be the sodium concentration of tubular fluid. The presence of increased sodium in the distal tubule is sensed by the macula densa cells (of the juxtaglomerular apparatus) and results in the secretion of renin into the afferent arteriole. The immediate effect on the glomerulus is to decrease filtration rate and hence the amount of sodium being presented to that tubule for reabsorbtion. This reduction in GFR has two main consequences: (i) a fall in sodium load to the tubule, and (ii) a subsequent reduction in the tubular oxygen demand. We clinically observe this as oliguria. This feedback mechanism has a number of potential beneficial effects: (i) autoregulation by each nephron of its own function; (ii) prevention oflarge losses of sodium and water when tubular function is impaired, e.g. ARF; (iii) a protective mechanism to reduce tubular cell oxygen demand; and, (iv) to optimise each nephron's oxygen supply vs demand balance. TGF can be seen to be an important mechanism for control of renal oxygen demand vs supply by allowing each nephron to match tubular oxygen demand to the available supply ( Figure 5 ). A drop in blood flow will result in a fall in oxygen supply to the tubule and a consequent reduction in sodium reabsorbtion. This activates the feedback mechanism to further reduce GFR and the metabolic demand (sodium load) placed on the tubule. The resulting oliguria is then a clinical sign of an appropriate physiological response described by Thurau and Baylon 47 as a sign of 'acute renal success'.
Conversely a small rise in RBF may be adequate to reverse tubular cell hypoxia. Dopamine, therefore, has theoretical advantages in the setting of imminent renal ischaemia by:
(i) increasing oxygen supply (RBF); and, (ii) reducing oxygen demand (reduced sodium reabsorbtion -see below).
The clinical importance of urine output
Urine output has a wide physiological range from about 0,5 to 8 mllkg/hr. Unlike RBF and GFR, urine output is quite sensitive to changes in blood volume, cardiac output, blood pressure ( Figure 2 ) and the precarious tubular supply/demand balance (Figure 4) . Unlike RBF and GFR, urine output is easily measured.
Urine output, while sensitive to many factors, is also as sensitive to the renal oxygen supply/demand balance -as long as tubular dysfunction is not present. 6 ,41 Tubular dysfunction may occur when there is either altered reabsorbtion or blunted TGF, e,g.:
(i) with the use of diuretics, (ii) with an osmotic diuresis (glycosuria, mannitol, urea), (iii) with the use of nephrotoxic agents, or (iv) in the polyuric phase of acute renal failure.
Dopamine in the setting of renal dysfunction
Prevention of renal dysfunction involves the protection of tubular function (and the oxygen supply/demand balance) through restoration of:
(i) blood volume; (ii) cardiac output/oxygen deliveryat normal or supra-normal levels; (iii) renal perfusion pressure (MAP = 90-95 mmHg), since autoregulation may be impaired; and (iv) renal blood flow.
To this end, dopamine has found a secure place in the armamentarium of the intensivist 1, 4, 12, 13, 48 both as an inotrope and a 'renal protecti~e' agent.
Dopamine has significant renal and cardiorespiratory side-effects (Table 1) and therefore it is important to balance the risk/benefit of its use. First let us examine the effects of dopamine on renal tubular function. 
Dopamine synthesis and dopamine receptors in the renal tubule
It has been noted for some years, both in animals and humans, that urine contained considerable quantities of dopamine. 56 Exogenous (filtered) dopamine cannot be the source as arterial levels are much lower than urine levels. Some dopamine may come from neural release, but current evidence suggests that the bulk of urinary dopamine is formed by the proximal tubular ce1l 56 ,57 ( Figure 6 ).
Circulating I-dopa is avidly extracted by tubular cells 56 ,57 ( Figure 6 ). These cells also contain dopaminergic receptors and l-aminodecarboxylase, the enzyme which catalyses the conversion of I-dopa to dopamine. The receptors are dopamine-l (DA 1 ) receptors and result in adenylate cylase activation and elevation of cAMP levels. 58 ,59 Dopamine produces inhibition of Na + /K + / ATPase activity on the tubular cell membrane. 57 Infusion of exogenous dopamine or I-dopa has the same effect. 56 ,57 An increase in sodium intake (or tubular sodium load) also increases l-amino- decarboxylase activity, urinary dopamine levels and inhibits tubular Na + /K + / ATPase. 60,61 ' Thus, intra-renal dopamine appears to be an important physiological regulator of tubular sodium reabsorbtion 62 ( Figure 6 ), stimulating sodium excretion. 57 This tubular or 'diuretic' effect has been demonstrated in the rat,61 dog,63 rabbit 5 & and human kidney. 60, 64 Intricate studies of nephron function have also revealed that dopamine impairs tubulo-glomerular feedback, independent of its tubular effects. 65 The exact mechnism and the significance are as yet unclear. On the one hand, an increased GFR will ~ncrease sodium load to the tubule and may mcrease tubular oxygen demand, thus jeopardising cell survival. On the other hand, blunting oftubuloglomerular feedback will increase GFR and urine output in the oliguric kidney.
A possible second-messenger role for the vasodilatory prostaglandin PGE 1 has also been suggested. Manoogian41 has shown that dopamine infusion (1 Ilglkglmin) resulted in increased urinary 6-keto-PGF la, a stable metabolite of PG El' It is possible that dopamine may mediate tubular and/or vascular effects via prostaglandins. 41 ,42 Interestingly, the renal tubular effects of dopamine are impaired by many commonly used drugs, e.g. dopamine-antagonists (metoclopramide,62 carbidopa,66 haloperidoI 58 ), cyclo-oxygenase inhibitors (ibuprofen42) and calcium antagonists (nifedipine 41 ). Metoclopramide may independently alter RBF.67,68
Does neural dopamine cause vasodilatation?
The renal hilum contains a rich network of sympathetic (T6-10) and some parasympathetic (vagal) fibres, supplied by the splanchnic nerves. The sympathetic fibres are primarily adrenergic, releasmg both noradrenaline and dopamine. Noradrenaline increases efferent then afferent vascular tone (a-receptor), and releases renin from the juxtaglomerular apparatus (~I-receptor). [14] [15] [16] Dopamine 69 -72 acts on a-and ~-receptors, both directly and indirectly 70 via displacement of noradrenaline. Dopamine is also known to act on dopaminergic 71 ,72 receptors at sympathetic nerve terminals. First, it acts on post-synaptic DAl receptors to modulate the effects of adrenergicreceptor stimulation. Second, it acts on presynaptic DA2 receptors to reduce further release of neurotransmitter.
Thus blockade of adrenergic receptors (with specific a-and ~-antagonists) results in the unmasking of a vasodilatory response to exogenous dopamine infusion. 72 In vitro animal studies I2 ,72-75 lend support to the concept that dopaminergic receptors can mediate vasodilatation in a number of vascular beds, including coronary, mesenteric and renal. In addition, the existence of specific dopaminergic neurones, either sympathetic 75 ,76 or parasympathetic,77 has been inferred from histochemical studies. Some have also suggested that neural dopamine is the only source likely to achieve adequately high concentrations required to elicit vasodilatation. 75 Although the existence of dedicated dopaminergic neurones is quite probable,14-78 their function remains unproven. The overwhelming effect from stimulation of the renal nerve plexus is vasoconstriction. 66. 78-80 Even prior administration of a-antagonists does not unmask the presence of any significant renal vasodilatory response. 79 The work by Baines and Drangova 66 suggests that dopaminergic neurones may well increase GFR, but whether this is by vasodilatation, inhibition of TGF, or another mechanism remains unclear.
Does exogneous dopamine cause renal vasodilatation?
Nevertheless, dopamine-induced renal vasodilatation does appear to be supported by many researchers. There are numerous animaI 12 ,72,80,81 and human studies 12.13.82-84 purporting to demonstrate renal vasodilatation following dopamine administration_ There are many clinical reports 85 -91 of apparent reversal in renal dysfunction following dopamine infusions. Finally there is much anecdotal evidence of improvement in urine output and renal function when low-dose dopamine is used in critically ill patients.
One of the major difficulties in researching the effects of dopamine on renal function is the failure to adequately control for its many direct and indirect renal actions ( Figure I ). These include:
(i) a rise in cardiac output, (ii) a rise in renal perfusion pressure, (iii) a 'diuretic' effect on tubular function, as well as (iv) a localised effect on renal vascular resistance -a true renal vasodilator effect. To differentiate these effects especially during clinical studies is often difficult. Most of the dopamine studies in humans and many of the animal studies have not considered them. A number of other common methodological problems must also be considered:
(i) dopamine alters PAH extraction,92 therefore unless a renal vein catheter is used, P AH clearance (the most widely used estimate of RBF) is invalid; (ii) plasma dopamine levels correlate poorly with the infused dose,93 especially in critically ill patients, due to altered clearance; (iii) nearly all dopamine studies are unblinded; and (iv) most animal research is carried out on anaesthetised subjects.
Animal studies into the renal effects of dopamine
Much of the early animal research purported to demonstrate direct renal vasodilatation in response to dopamine. In the important study by McN ay and Goldberg,94 a 28% fall in renal vascular resistance was demonstrated in response to low-dose (3 ~g!kg! min) dopamine. Cardiac output was also increased, but to a lesser extent (11 %). Kapusta and Robie 80 also showed improved RBF with dopamine infusion, but only at a low MAP level (below the normal autoregulatory range). Hardaker and Wechsler,95 using a micro sphere technique in dogs, showed that dopamine produced increased RBF and redistribution of cortical flow towards the inner cortex.
Unfortunately in these (and most other) studies the animals were observed under general anaesthesia, which, as mentioned above, will alter renal haemodynamics. Dopamine may reverse these effects. 80, 96 In addition, cardiac output was not measured in the later reports. 80 ,95 Nevertheless this data does support the hypothesis that dopamine is a direct renal vasodilator.
Conversely, there are many studies which have not demonstrated renal vasodilatation. The use of an 'isolated kidney' preparation enables some of the extra-renal variables to be controlled more easily. For example, McGrath et al.,97 in a controlled study using isolated perfused rat kidneys, observed neither an increase in RBF nor GFR following low-and high-dose dopamine. Perfusion pressure was held constant throughout. They did find increased sodium and water excretion and inferred the presence of a tubular effect, which was reversed with a dopamine antagonist (Spiperone). In another study using denervated rat kidneys, very little vasodilatation was noted with dopamine infusion. 66 Only in the presence of combined u-and /3-receptor blockade, and only with high-dose dopamine, was there a small (4%) fall in renal vascular resistance.
Davis et al. 98 studied the mechanism of increased sodium excretion with dopamine in 'awake' dogs, using microtubular probes. A dose of 10 /J.g/kg/min produced an increased sodium excretion without a demonstrable effect on GFR, again suggesting an isolated 'diuretic' effect. Similarly, Wasserman et al.,99 using dopamine in anaesthetised cats, demonstrated a rise in MAP and a smaller rise in RBF, but calculated renal vascular resistance actually rose, implying vasoconstriction. Urine output and urine sodium excretion rose but not GFR, again implying a tubular (diuretic) effect. Admittedly species differences or predominant alpha-effects could have possibly accounted for some of these variations.
Human studies into the renal effects of dopamine
Two of the most commonly referenced studies to support dopaminergic renal vasodilatation in man come from Hollenberg et al. 82 and McDonald et al.
Hollenberg et al. 82 studied RBF using haemodynamic and angiographic techniques in healthy kidney donors during dopamine infusion. Dose-related effects were found as follows: 3 /J.g/kg/ min produced a maximal increase in RBF without changes in heart rate or MAP; and a fall in RBF back to control levels occurred at > 5 /J.g/kg/min.
These subjects all were given intravenous saline during study and this itself may produce an increase in RBF. 14, 58 No record of urine flow nor cardiac output was made, and an observed increase slope of the upstroke in the pulse pressure wave (possibly due to an increase in cardiac output) was not discussed.
More recently Stevens et al. 100 used duplexdoppler analysis of renal flow, 84 and showed significant increases with dopamine 2 /J.g/kg/min. Once again cardiac output was not measured,lol and despite a significant rise in heart rate (14%) they concluded that dopamine only had 'a direct effect on renal vasculature'.
McDonald et al.,83 studied nine healthy adults given dopamine 4 to 7 /J.g/kg/min. The dose was individualised and pre-determined to be the highest dose which did not cause a rise in MAP.
Their results showed that dopamine was associated with increased GFR (inulin clearance), sodium excretion, and RBF (PAH clearance). However there were a number of problems with the study. All subjects were given a loading dose of water (15-20 ml/kg) immediately prior to study. This produced high urine output at baseline (5-16 ml/min), i.e. all were polyuric to start with! During dopamine infusion only small increases in GFR were noted and urine output did not significantly increase, but there was a large increase in sodium excretion. Cardiac index was measured in five of the subjects -all showed an increase (mean rise of 1.4 lImin/m2, or 47%) during the infusion. The renal fraction of cardiac output remained unchanged, thus suggesting the rise in RBF to be a secondary phenomenon. That is, renal vasodilatation may simply be part of an overall systemic vasodilatation in response to a rise in cardiac output.
Other studies have shown similar increases in cardiac output with low-dose dopamine in healthy subjects,92,lo2 and in post-cardiac surgerylOl-I04 and critically ill 105 patients, Cardiac output may be elevated by up to 20% with 'low-dose' dopamine, with or without an increase in MAP. Therefore the increase in RBF may be primarily attributable to cardiac effects l0l ,lo3.107 rather than a direct renovascular effect.
The effect of other catecholamines on renal blood flow
If the effects of dopamine on RBF are mainly due to its systemic cardiovascular effects, then other catecholamines may also augment RBF. Following cardiac surgery, dobutamine, dopexamine, and dopamine all increase RBF in proportion to the rise in cardiac output,103,107-110 while in patients with congestive cardiac failure dobutamine produces a greater rise in creatinine clearance than dopamine. 110 Adrenaline and noradrenaline have become increasingly popular in patients with septic shock. 69 ,111-116 In septic sheep adrenaline (5 to 40 /J.g/min) produces an initial dose-dependent fall in RBF; however by 30 minutes RBF returns to, and tends to rise above, baseline. 117 Similar data has been reported with noradrenaline. 32 ,111-114,118,119 
Is dopamine a renal vasodilator?
Despite in vitro data suggesting dopamine has vasodilatory properties, the existence of clinically significant direct renal vasodilatation remains, at best, unproven. Many of the animal and human studies have been poorly controlled. The weight of current evidence does however support an indirect increase in RBF secondary to a rise in cardiac output, even with low doses. A 'diuretic' effect is also frequently noted, and this follows from the specific tubular-cell activity of dopamine.
Is dopamine a 'renal-protective' agent?
A rise in RBF (by whatever means) should potentially be advantageous in the setting of renal dysfunction. However, despite many reports of improvement in renal function following the use of dopamine, there are no properly controlled studies showing a reduced incidence of renal failure or mortality. Admittedly such a study would require large numbers, and it would be difficult to control for other important variables.
PoIson et al., 90 in a retrospective study of liver transplant recipients, showed that prophylactic dopamine improved creatinine clearance. Cardiac output was not measured, and therefore it was difficult to distinguish a specific dopaminergic benefit from a nonspecific ~-adrenergic benefit. It would not be surprising to find tl\,at patients then with augmented cardiac output had a better prognosis. 105,120 Despite these limitations this study is currently the nearest to a controlled trial!
In terms of renal protection this drug may be a 'double-edged sword'. On the one hand the potential renal benefits of dopamine are, (i) an increase in oxygen delivery via a moderate rise in cardiac output, and usually a rise in RBF; and, (ii) a potential decrease in renal oxygen demand, through inhibition of sodium reabsorbtion. On the other hand, although the accompanying diuresis may make the fluid balance look better and the clinician feel better, dopamine may also obscure potential harm, since:
(i) dopamine impairs the important TGF mechanism which may adversely affect the oxygen supply/demand balance; (ii) the diuresis is not always associated with augmentaton of RBF; (iii) the diuresis may mask hypovolaemia or renal hypoperfusion; and, (iv) an inappropriate diuresis may produce hypovolaemia. To put it more bluntly, should we use an agent with significant diuretic properties in the oliguric patient?
In addition it must be noted that, (i) similar augmentation of renal flow would appear to be achievable with other catecholamines which do not interfere with tubular function; (ii) the tubular, and possibly other DA1-receptor, effects of dopamine are inhibited by commonly-used drugs (see above); and (iii) dopamine produces multiple adverse cardiorespiratory side-effects (Table 1) .
CONCLUSION
The important question, is dopamine beneficial to renal function? currently remains unanswered. As it stands however, there is sufficient evidence to question its regular use in the setting of renal dysfunction, especially in the critically ill patient.
The few available clinical reports of improvement in renal function following the use of dopamine have not been adequately conducted. Nor have they addressed the question of a specific dopaminergic or 'renal protective' benefit, over and above its ~-adrenergic (or inotropic) action. 'Low-dose dopamine' would appear to be more or less equivalent to a 'diuretic' with moderate inotropic properties, and possibly some renal vasodilator properties.
If dopamine is used, then greater attention must be paid to the basic elements of critical careblood volume, renal perfusion pressure (MAP), and cardiac output -as urine output can no longer be used as a guide to the adequacy of RBF.
